{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:34:01Z","timestamp":1787762041720,"version":"build-2784847793"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Cytokine storm in coronavirus disease 2019 (COVID-19) patients leads to acute lung injury, acute respiratory distress syndrome, multiorgan dysfunction, shock, and thrombosis thus contributing to significant morbidity and mortality. Several agents like steroids, ascorbic acid, vitamins (C, D, E), glutathione, N-acetylcysteine have been used and several studies are underway to identify its efficacy in addressing undesirable effects due to COVID-19 illness. Among several experimental modalities based on expert opinion and anecdotal data, melatonin is one molecule that appears promising. Owing to its anti-inflammatory, anti-oxidant, and immunomodulatory properties, melatonin can be an important agent used as a component of multimodal analgesia in COVID-19 patients, suspected patients, and patients with exposure to positive patients undergoing emergency or urgent surgeries. Further research is required to know the optimal time of initiation, dose, and duration of melatonin as an adjunct.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/2045-9912.325990","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T05:26:52Z","timestamp":1686547612000},"page":"41-43","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Perioperative melatonin in COVID-19 patients"],"prefix":"10.4103","volume":"12","author":[{"given":"Abhijit S.","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240907","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3389\/fimmu.2020.01441","article-title":"Immune response, inflammation, and the clinical spectrum of COVID-19","volume":"11","author":"Garc\u00eda","year":"2020","journal-title":"Front Immunol"},{"key":"R2-2-20240907","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"R3-2-20240907","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2020.05.003","article-title":"The cytokine storm in COVID-19: an overview of the involvement of the chemokine\/chemokine-receptor system","volume":"53","author":"Coperchini","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"R4-2-20240907","doi-asserted-by":"crossref","first-page":"100738","DOI":"10.1016\/j.nmni.2020.100738","article-title":"COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics","volume":"37","author":"Azer","year":"2020","journal-title":"New Microbes New Infect"},{"key":"R5-2-20240907","doi-asserted-by":"crossref","first-page":"118336","DOI":"10.1016\/j.lfs.2020.118336","article-title":"COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic","volume":"261","author":"Bhavana","year":"2020","journal-title":"Life Sci"},{"key":"R6-2-20240907","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/ph13080188","article-title":"Emerging therapeutic modalities against COVID-19","volume":"13","author":"Malik","year":"2020","journal-title":"Pharmaceuticals (Basel"},{"key":"R7-2-20240907","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.2174\/0929867321666131227163352","article-title":"CD147: a novel modulator of inflammatory and immune disorders","volume":"21","author":"Zhu","year":"2014","journal-title":"Curr Med Chem"},{"key":"R8-2-20240907","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12015-020-09976-7","article-title":"CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement","volume":"16","author":"Ulrich","year":"2020","journal-title":"Stem Cell Rev Rep"},{"key":"R9-2-20240907","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"R10-2-20240907","doi-asserted-by":"crossref","first-page":"110102","DOI":"10.1016\/j.mehy.2020.110102","article-title":"SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression","volume":"143","author":"Cecchini","year":"2020","journal-title":"Med Hypotheses"},{"key":"R11-2-20240907","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/rej.2015.1704","article-title":"Melatonin: a potential anti-oxidant therapeutic agent for mitochondrial dysfunctions and related disorders","volume":"19","author":"Ganie","year":"2016","journal-title":"Rejuvenation Res"},{"key":"R12-2-20240907","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/jpi.12162","article-title":"Melatonin: a well-documented antioxidant with conditional pro-oxidant actions","volume":"57","author":"Zhang","year":"2014","journal-title":"J Pineal Res"},{"key":"R13-2-20240907","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2174\/1568026615666150220120946","article-title":"Antioxidant properties of melatonin and its potential action in diseases","volume":"15","author":"Karaaslan","year":"2015","journal-title":"Curr Top Med Chem"},{"key":"R14-2-20240907","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/jpi.12360","article-title":"Melatonin as an antioxidant: under promises but over delivers","volume":"61","author":"Reiter","year":"2016","journal-title":"J Pineal Res"},{"key":"R15-2-20240907","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1007\/s00018-017-2609-7","article-title":"Melatonin as a mitochondria-targeted antioxidant: one of evolution\u2019s best ideas","volume":"74","author":"Reiter","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"R16-2-20240907","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.3390\/ijms14048638","article-title":"Melatonin: buffering the immune system","volume":"14","author":"Carrillo-Vico","year":"2013","journal-title":"Int J Mol Sci"},{"key":"R17-2-20240907","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3390\/ijms20051223","article-title":"Aging, melatonin, and the pro- and anti-inflammatory networks","volume":"20","author":"Hardeland","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R18-2-20240907","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1749-6632.2009.04896.x","article-title":"Intracellular prooxidant activity of melatonin induces a survival pathway involving NF-kappaB activation","volume":"1171","author":"Cristofanon","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"R19-2-20240907","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-079X.2009.00737.x","article-title":"Pharmacokinetics of orally administered melatonin in critically ill patients","volume":"48","author":"Mistraletti","year":"2010","journal-title":"J Pineal Res"},{"key":"R20-2-20240907","doi-asserted-by":"crossref","first-page":"6403967","DOI":"10.1155\/2019\/6403967","article-title":"Melatonin rescued reactive oxygen species-impaired osteogenesis of human bone marrow mesenchymal stem cells in the presence of tumor necrosis factor-alpha","volume":"2019","author":"Qiu","year":"2019","journal-title":"Stem Cells Int"},{"key":"R21-2-20240907","doi-asserted-by":"crossref","first-page":"100582","DOI":"10.18632\/oncotarget.21504","article-title":"Exogenous melatonin in the treatment of pain: a systematic review and meta-analysis","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"R22-2-20240907","first-page":"274","article-title":"Melatonin and its agonists in pain modulation and its clinical application","volume":"150","author":"Srinivasan","year":"2012","journal-title":"Arch Ital Biol"},{"key":"R23-2-20240907","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.brainresbull.2009.12.001","article-title":"Potential use of melatonergic drugs in analgesia: mechanisms of action","volume":"81","author":"Srinivasan","year":"2010","journal-title":"Brain Res Bull"},{"key":"R24-2-20240907","first-page":"10","article-title":"Melatonin is significantly associated with survival of intubated COVID-19 patients","volume":"doi","author":"Ramlall","year":"2020","journal-title":"medRxiv"},{"key":"R25-2-20240907","doi-asserted-by":"crossref","first-page":"e12683","DOI":"10.1111\/jpi.12683","article-title":"Clinical trial to test the efficacy of melatonin in COVID-19","volume":"69","author":"Acu\u00f1a-Castroviejo","year":"2020","journal-title":"J Pineal Res"},{"key":"R26-2-20240907","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s13063-020-04632-4","article-title":"A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Rodr\u00edguez-Rubio","year":"2020","journal-title":"Trials"},{"key":"R27-2-20240907","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1186\/s13063-020-04819-9","article-title":"Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Emadi","year":"2020","journal-title":"Trials"},{"key":"R28-2-20240907","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3390\/nu12092561","article-title":"Clinical trials for use of melatonin to fight against COVID-19 are urgently needed","volume":"12","author":"Kleszczy\u0144ski","year":"2020","journal-title":"Nutrients"},{"key":"R29-2-20240907","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00228-015-1873-4","article-title":"Clinical pharmacokinetics of melatonin: a systematic review","volume":"71","author":"Harps\u00f8e","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"R30-2-20240907","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/s-0040-1721658","article-title":"A review on mode of delivery during COVID-19 between December 2019 and April 2020","volume":"38","author":"Debrabandere","year":"2021","journal-title":"Am J Perinatol"},{"key":"R31-2-20240907","first-page":"963","article-title":"Evaluation of the analgesic efficacy of melatonin in patients undergoing cesarean section under spinal anesthesia: a prospective randomized double-blind study","volume":"15","author":"Beigom Khezri","year":"2016","journal-title":"Iran J Pharm Res"}],"container-title":["Medical Gas Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/2045-9912.325990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:13:17Z","timestamp":1787760797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2045-9912.325990"}},"subtitle":["benefits beyond sedation and analgesia"],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/2045-9912.325990","relation":{},"ISSN":["2045-9912"],"issn-type":[{"value":"2045-9912","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}